Summary & Overview
HCPCS Level II C9161: Injection, aflibercept hd, 1 mg
HCPCS Level II code C9161 denotes an injection of aflibercept hd, 1 mg — a high-dose formulation used primarily in ophthalmic care. This code identifies the administered drug unit and is used on outpatient professional and facility claims to indicate the biologic medication delivered during intravitreal procedures. Nationally, precise drug-level HCPCS codes like C9161 are important for drug tracking, reimbursement clarity, and specialty pharmacy capture.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how this code is classified and used in clinical billing, plus what to expect in typical sites of service such as ophthalmology offices and ambulatory surgical centers. Coverage and reimbursement practices can vary by payer, so analyses often compare contract-specific payment allowances, prior authorization requirements, and physician-administered drug billing pathways.
This publication provides benchmarks and policy-relevant context for C9161, outlines the clinical setting in which aflibercept hd is administered, and summarizes common billing considerations for professional and facility service lines. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code C9161 represents Injection, aflibercept hd, 1 mg. This code describes a single-dose injectable administration of aflibercept high-dose formulation at a 1 mg unit.
-
Service type: Intravitreal injection of a biologic agent for ophthalmic indications
-
Typical site of service: Office or ambulatory surgical setting where ophthalmic injections are performed
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with neovascular (wet) age-related macular degeneration or macular edema from diabetic retinopathy presenting to an ophthalmology clinic for intravitreal therapy. After a same-day evaluation by a retina specialist, informed consent, and topical anesthesia with povidone-iodine antisepsis, the provider prepares a sterile field and draws C9161 (injection, aflibercept hd, 1 mg) into a single-use syringe. The intravitreal injection is administered in the clinic procedure room or minor procedure suite with monitoring for immediate adverse events (pain, bleeding, increased intraocular pressure, endophthalmitis). Post-injection instructions and follow-up are arranged, including vision check and intraocular pressure assessment before discharge. Typical workflow steps: pre-procedure assessment and consent, medication preparation and documentation of lot number, topical anesthetic and antisepsis, intravitreal injection of C9161, post-injection observations, and scheduling of follow-up treatment or monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required for the injection is substantially greater than typical (e.g., severely scarred conjunctiva, complex anesthesia needs). |